Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study.

ABSTRACT:

Background

In the phase III FRESCO-2 study, overall survival (OS) was significantly improved with fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). Here, we present data from a FRESCO-2 subanalysis of patients enrolled in Spain.

Patients and methods

In FRESCO-2, patients had received all standard chemotherapies, anti-vascular endothelial growth factor and anti-epidermal growth factor receptor therapies, if indicated, and had progressed on or were intolerant to trifluridine/tipiracil (TAS-102) and/or regorafenib. Patients were randomized 2 : 1 to receive fruquintinib 5 mg orally or matching placebo once daily for 21 days in 28-day cycles, plus BSC. The primary endpoint was OS; secondary endpoi

SUBMITTER: Garcia-Carbonero R 

PROVIDER: S-EPMC12836649 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature